These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 26070500)
1. Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. Merkle EM; Zech CJ; Bartolozzi C; Bashir MR; Ba-Ssalamah A; Huppertz A; Lee JM; Ricke J; Sakamoto M; Sirlin CB; Ye SL; Zeng M Eur Radiol; 2016 Mar; 26(3):674-82. PubMed ID: 26070500 [TBL] [Abstract][Full Text] [Related]
2. Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. Zech CJ; Ba-Ssalamah A; Berg T; Chandarana H; Chau GY; Grazioli L; Kim MJ; Lee JM; Merkle EM; Murakami T; Ricke J; B Sirlin C; Song B; Taouli B; Yoshimitsu K; Koh DM Eur Radiol; 2020 Jan; 30(1):370-382. PubMed ID: 31385048 [TBL] [Abstract][Full Text] [Related]
3. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma]. Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944 [TBL] [Abstract][Full Text] [Related]
4. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994 [TBL] [Abstract][Full Text] [Related]
5. Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers. Kim YY; Park MS; Aljoqiman KS; Choi JY; Kim MJ Clin Mol Hepatol; 2019 Sep; 25(3):223-233. PubMed ID: 30661336 [TBL] [Abstract][Full Text] [Related]
6. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient. Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959 [TBL] [Abstract][Full Text] [Related]
7. Consensus report from the 9 Koh DM; Ba-Ssalamah A; Brancatelli G; Fananapazir G; Fiel MI; Goshima S; Ju SH; Kartalis N; Kudo M; Lee JM; Murakami T; Seidensticker M; Sirlin CB; Tan CH; Wang J; Yoon JH; Zeng M; Zhou J; Taouli B Eur Radiol; 2021 Aug; 31(8):5615-5628. PubMed ID: 33523304 [TBL] [Abstract][Full Text] [Related]
8. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319 [TBL] [Abstract][Full Text] [Related]
9. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI. Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786 [TBL] [Abstract][Full Text] [Related]
10. Consensus report from the 6th International forum for liver MRI using gadoxetic acid. Sirlin CB; Hussain HK; Jonas E; Kanematsu M; Min Lee J; Merkle EM; Peck-Radosavljevic M; Reeder SB; Ricke J; Sakamoto M J Magn Reson Imaging; 2014 Sep; 40(3):516-29. PubMed ID: 24923695 [TBL] [Abstract][Full Text] [Related]
12. Value of Texture Analysis on Gadoxetic Acid-Enhanced MRI for Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia. Cannella R; Rangaswamy B; Minervini MI; Borhani AA; Tsung A; Furlan A AJR Am J Roentgenol; 2019 Mar; 212(3):538-546. PubMed ID: 30557050 [TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis. Fowler KJ; Brown JJ; Narra VR Hepatology; 2011 Dec; 54(6):2227-37. PubMed ID: 21932400 [TBL] [Abstract][Full Text] [Related]
14. Consensus report of the Fifth International Forum for Liver MRI. Zech CJ; Bartolozzi C; Bioulac-Sage P; Chow PK; Forner A; Grazioli L; Huppertz A; Laumonier H; Min Lee J; Murakami T; Ricke J; Sirlin CB AJR Am J Roentgenol; 2013 Jul; 201(1):97-107. PubMed ID: 23789662 [TBL] [Abstract][Full Text] [Related]
15. Management of subcentimetre arterially enhancing and hepatobiliary hypointense lesions on gadoxetic acid-enhanced MRI in patients at risk for HCC. Park CJ; An C; Park S; Choi JY; Kim MJ Eur Radiol; 2018 Apr; 28(4):1476-1484. PubMed ID: 29063251 [TBL] [Abstract][Full Text] [Related]
16. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. Lee MH; Kim SH; Park MJ; Park CK; Rhim H AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings. Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131 [TBL] [Abstract][Full Text] [Related]
19. Detection of small hepatocellular carcinoma using gadoxetic acid-enhanced MRI: Is the addition of diffusion-weighted MRI at 3.0T beneficial? Zhao XT; Li WX; Chai WM; Chen KM J Dig Dis; 2014 Mar; 15(3):137-45. PubMed ID: 24354621 [TBL] [Abstract][Full Text] [Related]
20. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. Chong YS; Kim YK; Lee MW; Kim SH; Lee WJ; Rhim HC; Lee SJ Clin Radiol; 2012 Aug; 67(8):766-73. PubMed ID: 22425613 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]